Primary Hypertension Clinical Trial
Official title:
Multi-Omics to Predict the Blood Pressure Response to Antihypertensives
The goal of this clinical trial is to develop biomarkers composed of multiple OMICs (MOMICs) for prediction of blood pressure response to antihypertensive drugs in the treatment of primary hypertension. The main objectives are: - Primary objective: - To identify MOMICs biomarkers that predict the response in 24-hour blood pressure to antihypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine) - Secondary objectives: - To identify a MOMICs biomarker that predict the response in night-time blood pressure to anti-hypertensive treatment for each treatment group (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine) - To identify MOMICs biomarkers that predict side effects, including changes in QoLof olmesartan, amlodipine and hydrochlorothiazide. - Exploratory objective: - To assess changes in MOMICs biomarkers induced by each drug Participants will undergo three 4-week treatment periods: - Each subject receives 3 out of 4 possible treatments (olmesartan, amlodipine, hydrochlorothiazide, olmesartan/amlodipine). - Before and after each treatment period OMICS measurements and an ABPM are performed. - At the end of each treatment period blood is sampled for drug level testing to assess adherence. - Electrolytes and kidney function are checked 5-7 days after start of each treatment period.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00573742 -
Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients
|
N/A | |
Recruiting |
NCT06208072 -
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
|
N/A | |
Recruiting |
NCT06049862 -
The Effectiveness of "MaRiTensi" in Increasing Self-Care and Blood Pressure Control: Randomized Controlled Trial
|
N/A | |
Completed |
NCT00819104 -
A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components
|
Phase 4 | |
Not yet recruiting |
NCT06091176 -
Assessment of Efficacy and Safety of Amicomed®, for the Management of Essential Hypertension
|
N/A | |
Recruiting |
NCT01742702 -
HaemoDYNAMICs in Primary and Secondary Hypertension
|
||
Recruiting |
NCT02817204 -
Effect of Aerobic EXercise on MiCroVAscular RarefacTION in Chinese Mild HyperteNsive Patients(EXCAVATION-CHN1)
|
Phase 3 | |
Completed |
NCT00794885 -
China Stroke Primary Prevention Trial
|
Phase 4 | |
Active, not recruiting |
NCT04381520 -
Heat-sensitive Moxibustion Self-administration in Patients in the Community With Primary Hypertension: Protocol for a Multi-center, Pragmatic, Non-randomized Trial
|
N/A | |
Completed |
NCT00865501 -
Importance of Aldosterone in the Pathogenesis of Hypertensive Heart Disease
|
Phase 3 | |
Active, not recruiting |
NCT04788563 -
A Randomized Patient Preference Trial on Heat-sensitive Moxibustion for Primary Hypertension in Community
|
N/A | |
Completed |
NCT02184858 -
Dose Titration of Lisinopril in Children Aged 1 to 18 Years With Primary or Secondary Hypertension
|
Phase 4 | |
Completed |
NCT03105687 -
Effectiveness of SMS Reminders of Blood Pressure-lowering Drugs Intake
|
N/A | |
Completed |
NCT01392534 -
Effects of Telmisartan/Hydrochlorothiazide Treatment in Hypertensive Patients Under Real-life Setting
|
N/A | |
Active, not recruiting |
NCT03015311 -
Strategy of Blood Pressure Intervention in the Elderly Hypertensive Patients
|
N/A | |
Enrolling by invitation |
NCT03470974 -
The Effect of Self-Titration and Predictors for Blood Pressure Control in Patients With Hypertension
|
N/A | |
Active, not recruiting |
NCT01844570 -
Levamlodipine Maleate or Amlodipine Besylate for Treatment of Hypertension: A Comparative Effectiveness Research
|
N/A | |
Completed |
NCT01241487 -
A National Multicentre Study to Assess the Efficacy of the Fixed Combination of Valsartan and Amlodipine in Hypertensive Patients Not Controlled by Monotherapy
|
Phase 4 | |
Completed |
NCT00882947 -
Post-Marketing Surveillance of Ventavis® in Chinese Patients With Primary Pulmonary Hypertension (PPH)
|
Phase 4 | |
Active, not recruiting |
NCT03310684 -
Pediatric Primary Hypertension and the Renin-Angiotensin System (PHRAS)
|